NO20034561L - Use of cationic dextran derivatives for the protection of dose limiting organs - Google Patents

Use of cationic dextran derivatives for the protection of dose limiting organs

Info

Publication number
NO20034561L
NO20034561L NO20034561A NO20034561A NO20034561L NO 20034561 L NO20034561 L NO 20034561L NO 20034561 A NO20034561 A NO 20034561A NO 20034561 A NO20034561 A NO 20034561A NO 20034561 L NO20034561 L NO 20034561L
Authority
NO
Norway
Prior art keywords
dextran derivatives
cationic dextran
agents
protection
dose limiting
Prior art date
Application number
NO20034561A
Other languages
Norwegian (no)
Other versions
NO20034561D0 (en
Inventor
Anders Holmberg
Jukka Olavi Hiltunen
Giovanni Paganelli
Marta Cremonesi
Original Assignee
Map Medical Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Medical Technologies Oy filed Critical Map Medical Technologies Oy
Publication of NO20034561D0 publication Critical patent/NO20034561D0/en
Publication of NO20034561L publication Critical patent/NO20034561L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen frembringer anvendelse av kationiske dekstranderivater med substituenter med positivt ladede sidegrupper som beskyttende midler for dosebegrensende organer ved systemisk behandling av sykdommer inkludert cancer. De kationiske dekstranderivatene er spesielt nyttige som nefrobeskyrtende midler for et individ underlagt systemisk behandling med cytostatiske farmasøytika, forbindelser som bærer cytostatiske farmasøytika, radionuklider eller forbindelser som bærer radionuklider mot nyreskade. De kationiske dekstranderivatene beskytter ikke bare de dosebegrensende organene, men tolereres bedre og har færre bivirkninger enn tradisjonelt anvendte beskyttende midler.The present invention provides the use of cationic dextran derivatives with substituents with positively charged side groups as protective agents for dose limiting agents in the systemic treatment of diseases including cancer. The cationic dextran derivatives are particularly useful as nephroprotecting agents for an individual undergoing systemic treatment with cytostatic pharmaceuticals, compounds bearing cytostatic pharmaceuticals, radionuclides or compounds bearing radionuclides for renal damage. The cationic dextran derivatives not only protect the dose-limiting organs, but are better tolerated and have fewer side effects than traditionally used protective agents.

NO20034561A 2001-04-11 2003-10-10 Use of cationic dextran derivatives for the protection of dose limiting organs NO20034561L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010764A FI20010764A0 (en) 2001-04-11 2001-04-11 Cationic dextran derivatives for use in renal protection
PCT/FI2002/000305 WO2002083154A1 (en) 2001-04-11 2002-04-11 Use of cationic dextran derivatives for protecting dose-limiting organs

Publications (2)

Publication Number Publication Date
NO20034561D0 NO20034561D0 (en) 2003-10-10
NO20034561L true NO20034561L (en) 2003-12-09

Family

ID=8560975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034561A NO20034561L (en) 2001-04-11 2003-10-10 Use of cationic dextran derivatives for the protection of dose limiting organs

Country Status (13)

Country Link
EP (1) EP1383517A1 (en)
JP (1) JP2004525181A (en)
KR (1) KR20040018350A (en)
BR (1) BR0208860A (en)
CA (1) CA2443052A1 (en)
EE (1) EE200300502A (en)
FI (1) FI20010764A0 (en)
HU (1) HUP0401386A3 (en)
IL (1) IL158153A0 (en)
NO (1) NO20034561L (en)
PL (1) PL363024A1 (en)
RU (1) RU2003132683A (en)
WO (1) WO2002083154A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP3130396B1 (en) 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
EP2611530B1 (en) 2010-09-03 2019-01-16 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
DE102014016901B4 (en) * 2014-09-17 2021-08-12 Friedrich-Schiller-Universität Jena Process for the production of new dextran derivatives as active ingredient carrier systems and their use
WO2018100089A1 (en) * 2016-12-01 2018-06-07 Norbert Gretz Means and methods for visualization of tissue structures
EP4072563A4 (en) * 2019-12-14 2024-01-24 Manu Chaudhary Formulations of polybasic drugs to reduce multi-organ toxicity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3414491A1 (en) * 1984-04-17 1985-10-24 Hans Dr. 8202 Bad Aibling Dietl L-Amino acid mixtures for parenteral and oral use for kidney disorders
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
SE9803482D0 (en) * 1998-10-13 1998-10-13 Anders Holmberg Ion exchange tumor targeting (IETT)
AU6275800A (en) * 1999-07-16 2001-02-05 Mallinckrodt, Inc. Inhibition of renal uptake of molecules that are potentially damaging for the kidney

Also Published As

Publication number Publication date
PL363024A1 (en) 2004-11-15
NO20034561D0 (en) 2003-10-10
KR20040018350A (en) 2004-03-03
JP2004525181A (en) 2004-08-19
HUP0401386A2 (en) 2004-12-28
IL158153A0 (en) 2004-03-28
HUP0401386A3 (en) 2005-06-28
RU2003132683A (en) 2005-04-10
BR0208860A (en) 2004-10-19
CA2443052A1 (en) 2002-10-24
WO2002083154A1 (en) 2002-10-24
FI20010764A0 (en) 2001-04-11
EP1383517A1 (en) 2004-01-28
EE200300502A (en) 2003-12-15

Similar Documents

Publication Publication Date Title
ATE411022T1 (en) PYRIDYLPYRROLE DERIVATIVES AS EFFECTIVE KINASE INHIBITORS
NO20050795L (en) Compounds, compositions and methods for utilizing the same
NO20050497L (en) Use of CETP inhibitors and optionally HMG COA reducible inhibitors and / or antihypertensive agents
ATE511840T1 (en) IMIDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
ATE229506T1 (en) 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBONIC ACID DERIVATIVES AS SENSITIZERS FOR MULTI-DRUG-RESISTANT CANCER CELLS
NO20034561L (en) Use of cationic dextran derivatives for the protection of dose limiting organs
NO20073574L (en) Triazole-substituted aminobenzophenone compounds
HUP0103078A2 (en) Pharmaceutical compositions and methods for treating cataracts
CY1105008T1 (en) ANTIMICROBIAL ACTIVITY OF THE FIRST CATIONIC COMPLEX OF HUMAN LACTOFERRIN
ATE287267T1 (en) COMBINATION THERAPIES WITH VASCULAR DAMAGE ACTIVITY
MX2008008556A (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases.
MX2021015352A (en) Methods of treating fabry disease in patients having renal impairment.
NO20052059L (en) Chronic inflammatory demyelinating polyneuropathy therapies using interferon-beta.
BR0315437A (en) Hair treatment composition, uses and method of hair treatment
PT932613E (en) EXPRESSION OF BLOCKING VIRULENCE FACTS IN S. AUREUS
CY1110415T1 (en) ORIGINAL TETRICROCARBASOL PRODUCER ORIGINAL PROTECTION WITH IMPROVED BIOLOGICAL ACTION AND IMPROVED SOLUBILITY, AS CONDENSED CONDITIONERS
NO20060420L (en) 2 aminobenzoylderivater
NO20051561L (en) Nucleic acid molecules encoding human papillomavirus and their use in vaccine.
WO2005080549A3 (en) Trioxacarcins and their use against infections
TR200102557T2 (en) Thiazonlindolinone compounds.
BR112023019407A2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTANE
NO952601L (en) Oligonucleotides for Inhibition of Expression of Isoprenyl Protein Transferases
DE60008590D1 (en) COMPOSITIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS
ATE239466T1 (en) SORDARIN AND ITS DERIVATIVES AS FUNGICIDES FOR PLANT CULTURES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application